StreetAlpha
13F holdings · Q3 2026

Ishara Investments

Los Angeles, CA · files as Ishara Investments LP
Know the moment Ishara Investments filesYou follow Ishara Investments An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 2111609

Ishara Investments reported 40 stocks worth $120M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are TVTX (7.1%), CYTK (7.1%) and BBIO (5.5%). Compared with Q2 2026, the fund opened new positions in TARS, PTCT and ARQT, added to TVTX, CYTK and BBIO, trimmed ACAD, PRAX and XERS and sold out of AGIO, INSM and TNXP.

Latest filing: what Ishara Investments did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
16 new12 added12 trimmed17 sold outBought about $63.6M · sold about $65.8M
New 16
See all 16 →
Added 12
See all 12 →
Trimmed 12
See all 12 →
Sold out 17
See all 17 →

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$120M−12.2% vs last quarter · $121M including options
Stocks held4016 new · 17 sold out
Top 5 weight29.7%spread out
Turnover108%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 4 qtrsHeld
1
TVTX
Travere Therapeutics Inc
$8.5M7.1%145K+63K (+77%)3 of 4
2
CYTK
Cytokinetics Inc
$8.4M7.1%128K+95K (+290%)2 of 4
3
BBIO
Bridgebio Pharma Inc
$6.6M5.5%100K+43K (+74%)3 of 4
4
ACAD
Acadia Pharmaceuticals Inc
$6.4M5.4%320K−90K (−22%)4 of 4
5
TARS
Tarsus Pharmaceuticals Inc
$5.5M4.6%70KNew position2 of 4
6
PTCT
Ptc Therapeutics Inc
$5.2M4.3%80KNew position3 of 4
7
PRAX
Praxis Precision Medicines I
$5M4.1%17K−5,550 (−25%)4 of 4
8
VERA
Vera Therapeutics Inc
$4.8M4.0%150K+140K (+1363%)3 of 4
9
ARQT
Arcutis Biotherapeutics Inc
$4.8M4.0%180KNew position2 of 4
10
ANNX
Annexon Inc
$4.7M4.0%1.1M+300K (+37%)4 of 4
🔒 30 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
AGIO
Agios Pharmaceuticals Inc
$6.1M164K
INSM
Insmed Inc
$5.5M51K
CRINETICS PHARMACEUTICALS IN
$5.4M144K
TNXP
Tonix Pharmaceuticals Hldg C
$4.3M338K
KURA
Kura Oncology Inc
$3M277K

🔒 Free account: see all 17.

Options

valued at the underlying shares
StockTypeValueSharesChange
RARE
Ultragenyx Pharmaceutical in
Put$1.5M1,000+1,000

Reported value

last 4 quarters
$85.9MQ4 '25
$99MQ1 '26
$136MQ2 '26
$120MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Ishara Investments 13F FAQ

What does Ishara Investments own?

Ishara Investments reported 40 stocks worth $120M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are TVTX (7.1%), CYTK (7.1%) and BBIO (5.5%). The table above lists every position in the filing (the top 10 without an account).

What did Ishara Investments buy and sell in Q3 2026?

Compared with Q2 2026: 16 new positions, 12 added to, 12 trimmed and 17 sold out. New positions include TARS, PTCT and ARQT. It sold all of AGIO, INSM and TNXP.

When will Ishara Investments file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Ishara Investments's portfolio worth?

The Q3 2026 filing reports $120M in US stocks ($121M including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.